Site icon Fact.MR Blog

Pharmaceutical Coenzyme Q10 Applications Stay Dominant, Surging At 7% CAGR By 2031

Coenzyme Q10

Fact.MR predicts the sales of coenzyme Q10 market to exceed US$ 1.3 Bn by registering a CAGR of 8% in the forecast period 2021-2031. Increase in awareness regarding health and nutrition is playing a key role in the consumption of coenzyme Q10. By 2021, the market is expected to reach US$ 600 Mn.

Historically, between 2016 and 2020, the sales of coenzyme experienced a growth rate of 6%. Growth prospects received credible stimulus during COVID-19. A series of published studies hypothesizing the need to administer coenzyme Q10 in case of deficiencies experienced by patients during an infection kept prospects largely elevated.

Click Here To get a Sample Report (Including Full TOC, Table & Figures):-https://www.factmr.com/connectus/sample?flag=S&rep_id=732

Key Takeaways from the Market Study

 “As the growth of supplements and skin care nutrition is likely to be robust, coenzyme Q10 will be prominent with producers having an extensive product portfolio and the marketing prowess of products with nutritional and health benefits,” says the Fact.MR analyst.

Key Segments Covered

Competitive Landscape

Prominent players operating in the global coenzyme Q10 market include Kaneka Corporation, Xiamen Kingdomway Group, Nisshin Seifun Group, Zhejiang Medicine Co. Ltd, and Kyowa Hakko U.S.A. Inc., among others.

 

 

Exit mobile version